Phenylephrine extended-release

Drug Profile

Phenylephrine extended-release

Alternative Names: Phenylephrine extended-release - Schering-Plough; Phenylephrine HCl extended-release; Phenylephrine hydrochloride extended-release; SCH-002063

Latest Information Update: 11 May 2015

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Schering-Plough
  • Developer Bayer
  • Class Antihypotensives; Decongestants; Ethanolamines; Gene therapies; Mydriatics; Phenethylamines; Skin disorder therapies; Small molecules; Urologics
  • Mechanism of Action Alpha 1 adrenergic receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • No development reported Seasonal allergic rhinitis

Most Recent Events

  • 31 Oct 2011 Bayer completes a phase III trial for Seasonal allergic rhinitis in USA (NCT01413958)
  • 20 Oct 2011 Merck Sharp & Dohme completes enrolment in its phase III trial for Seasonal allergic rhinitis in USA (NCT01413958)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top